Lunsumio Drug Interactions
Currently displaying a list of 245 drugs known to interact with Lunsumio (mosunetuzumab).
- 34 major drug interactions
- 196 moderate drug interactions
- 15 minor drug interactions
Medications known to interact with Lunsumio
Note: Showing generic names only.
- abrocitinib
- adalimumab
- ado-trastuzumab emtansine
- alefacept
- alemtuzumab
- alfentanil
- allogeneic processed thymus tissue
- aminophylline
- amiodarone
- anakinra
- apixaban
- astemizole
- atezolizumab
- atomoxetine
- atorvastatin
- auranofin
- aurothioglucose
- avelumab
- axicabtagene ciloleucel
- azathioprine
- baricitinib
- bcg
- belimumab
- benznidazole
- bifidobacterium infantis
- bifidobacterium longum
- bortezomib
- brentuximab
- brewer's yeast
- brexpiprazole
- brexucabtagene autoleucel
- cabazitaxel
- canakinumab
- carbamazepine
- carboplatin
- carfilzomib
- cemiplimab
- cerivastatin
- certolizumab
- chloramphenicol
- chloramphenicol ophthalmic
- chloramphenicol otic
- chloroquine
- ciltacabtagene autoleucel
- cinoxacin
- ciprofloxacin
- cisapride
- cisplatin
- cladribine
- clozapine
- colchicine
- cosibelimab
- crizotinib
- cyclosporine
- dapsone
- deferiprone
- delafloxacin
- denosumab
- deucravacitinib
- dicumarol
- didanosine
- dihydroergotamine
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- disopyramide
- disulfiram
- docetaxel
- dostarlimab
- dronedarone
- durvalumab
- dyphylline
- efalizumab
- efbemalenograstim alfa
- eflapegrastim
- eliglustat
- elotuzumab
- elranatamab
- enfortumab vedotin
- enoxacin
- ergotamine
- eribulin
- etanercept
- ethambutol
- ethionamide
- etoposide
- etrasimod
- etravirine
- everolimus
- ezogabine
- idecabtagene vicleucel
- infliximab
- interferon alfa-2a
- interferon alfa-2b
- interferon alfa-n1
- interferon alfacon-1
- iodoquinol
- ipilimumab
- isoniazid
- ixabepilone
- ixazomib
- lactobacillus acidophilus
- lactobacillus reuteri
- lactobacillus rhamnosus
- lactobacillus rhamnosus gg
- leflunomide
- levodopa
- levofloxacin
- lidocaine
- linezolid
- lisocabtagene maraleucel
- lomefloxacin
- loncastuximab tesirine
- lovastatin
- lurbinectedin
- mephenytoin
- mesoridazine
- methadone
- metronidazole
- mexiletine
- mirvetuximab soravtansine
- monomethyl fumarate
- moxifloxacin
- nadofaragene firadenovec
- nalidixic acid
- natalizumab
- naxitamab
- nelarabine
- niraparib
- nitrofurantoin
- nivolumab
- norfloxacin
- paclitaxel
- paclitaxel protein-bound
- palifermin
- pegfilgrastim
- peginterferon alfa-2a
- peginterferon alfa-2b
- pembrolizumab
- penpulimab
- phenobarbital
- phenytoin
- pimozide
- pitavastatin
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- pravastatin
- primidone
- procainamide
- propafenone
- radium 223 dichloride
- red yeast rice
- repotrectinib
- retifanlimab
- rilonacept
- ritlecitinib
- rivaroxaban
- roflumilast
- ropeginterferon alfa-2b
- rosuvastatin
- ruxolitinib topical
- saccharomyces boulardii lyo
- samarium sm 153 lexidronam
- sargramostim
- secnidazole
- selinexor
- simvastatin
- siponimod
- sipuleucel-T
- sirolimus
- sodium phosphate p32
- sparfloxacin
- stavudine
- streptococcus salivarius
- strontium-89 chloride
- sunitinib
- tacrolimus
- talquetamab
- tarlatamab
- tbo-filgrastim
- teclistamab
- telbivudine
- temsirolimus
- teniposide
- terfenadine
- teriflunomide
- thalidomide
- theophylline
- thioridazine
- tinidazole
- tisagenlecleucel
- tislelizumab
- tisotumab vedotin
- tizanidine
- tocilizumab
- tofacitinib
- topotecan
- toripalimab
- trabectedin
- tremelimumab
- trovafloxacin
Report options
More about Lunsumio (mosunetuzumab)
- Lunsumio consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: bispecific T-cell engagers (BiTE)
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi (tafasitamab-cxix) is used for the treatment of relapsed or refractory diffuse large B-cell ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Yescarta
Yescarta is a CAR T-cell treatment used to treat relapsed or refractory large B-cell lymphoma ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Zynlonta
Zynlonta (loncastuximab tesirine) is used to treat relapsed or refractory diffuse large B-cell ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
